- 1 Impact of the COVID-19 pandemic on the uptake of intermittent sulphadoxine-pyrimethamine for
- 2 prevention of malaria amongst pregnant women in Sierra Leone
- 3 William Tilima Pessima<sup>1</sup>, Bailah Molleh<sup>2</sup>, Musa Silla-Kanu<sup>1</sup>, Brenda Stafford<sup>1</sup>, Wani Kumba Lahai<sup>1</sup>,
- 4 Dr Abdul Mac Falama<sup>1</sup>, Sharmistha Mishra<sup>3</sup>, Adrienne K. Chan<sup>3</sup>, Stephen Sevalie,<sup>2,4</sup> Sulaiman
- 5 Lakoh,<sup>1,2</sup> Michael Lahai<sup>5,6</sup>

# 6 Affiliations:

- 7 <sup>1</sup> National Malaria Control Programme, Ministry of Health, Freetown, Sierra Leone
- 8 <sup>2</sup> Sustainable Health Systems, Freetown, Sierra Leone
- 9 <sup>3</sup> Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of
- 10 Toronto, Toronto, Canada
- 11 <sup>4</sup> 34 Military Hospital, Wilberforce, Freetown, Sierra Leone
- <sup>5</sup> Faculty of Pharmaceutical Sciences, University of Sierra Leone, Freetown, Sierra Leone
- 13 <sup>6</sup> Pharmacy Board of Sierra Leone, Government of Sierra Leone, Freetown, Sierra Leone

- 15 Short title: Impact of COVID-19 on malaria prevention in pregnant women in Sierra Leone
- 16 Corresponding author: Sulaiman Lakoh (lakoh2009@gmail.com, +23278287492)
- 17
- 18
- 19
- 20

## 21 Abstract

Background: Malaria in pregnancy contributes to high maternal mortality, warranting the adoption
of intermittent preventive treatment (IPTp) of malaria in pregnancy in Sierra Leone in 2017. Since
then, the uptake of IPTp has increased but it is unclear whether COVID-19 has any impact on these
services. We aimed to assess the impact of COVID-19 on the uptake of IPTp among pregnant
women in Sierra leone at district, regional, and national levels.

Methods: A retrospective cross-sectional study design was used to assess the monthly aggregated
data from DHIS2 for all 5 regions of Sierra Leone. We describe the trends of IPTp1, IPTp2, and
IPTp3+ uptake at national, regional, and district levels before, during and after COVID-19. Data was
analyses using STATA. The median and interquartile range for each outcome in each period were
calculated.

Results: The median monthly uptake of total IPTp was the lowest before COVID (53,244) but increased during COVID-19 (55,257) and after COVID-19 (59,439). IPTp1 uptake was lowest during COVID-19 (20,338) but highest after COVID-19 (20,914). All three variables (IPTp1, IPTp2 and IPTp3) showed a clear decline in uptake in early 2020 and recovered within 3 months in a similar pattern of magnitude, except in Eastern Sierra Leone. Both IPTp2 and IPTp3 showed more pronounced increases in uptake after recovery than IPTp1 and they both experienced sustained increases in the post-COVID-19 period.

Conclusion: The negative impact of the COVID-19 pandemic in reducing IPTp uptake was followed
by rapid recovery, underscoring the resilience of the Sierra Leone's health system in response to
public health emergencies. However, the delay in recovery in the IPTp uptake in the Eastern Sierra

- 42 Leone highlight the need for strong differentiated regional strategies in protecting essential health
- 43 services during public health emergencies.
- 44 **Keywords:** IPTp, Malaria in pregnancy, COVID-19, Sierra Leone, Sulphadoxine-pyrimethamine

#### 46 Introduction

47 Malaria is responsible for 822,000 children with low birth weight in sub-Saharan Africa, more than half of which occur in the West African region (1). About 6% of malaria deaths in sub-Saharan 48 Africa are due to low birth weight (2). Historically, low birth weight has been a major problem in 49 50 Sierra Leone, caused mostly by infections such as malaria (3). Malaria in pregnancy is associated with a range of complications, including low birth weight, maternal hypoglycemia, intrauterine 51 growth retardation, placental malaria, fetal hypotrophy, miscarriage, abortion, anaemia and 52 53 preterm delivery, which explains the contribution of malaria to higher maternal and neonatal 54 mortality rates (4). A meta-analysis of studies primarily from sub-Saharan Africa showed that successful implementation of malaria and other interventions could reduce the risk of anaemia 55 and child mortality (5). 56

Intermittent Preventive Treatment for malaria in pregnancy (IPTp) with Sulfadoxine-57 58 Pyrimethamine (SP) is an evidence-based programmatic intervention that can prevent the adverse outcomes of malaria in pregnancy (1). Strong programmatic efforts by national and international 59 agencies, supported by political commitment, are needed to achieve substantial progress in the 60 uptake of IPTp-SP and, in turn, reduce the prevalence of malaria in pregnancy (6). Over the past 61 decade, most sub-Saharan African countries, including Sierra Leone, have introduced IPTp policies 62 for pregnant women. The current policy of the Sierra Leone malaria programme is to administer 63 64 IPTp-SP at 13 weeks of gestation since 2017 and every four weeks thereafter. Similar policies had been implemented in other African countries (7) (8). Similar policies had been implemented in 65 other African countries (7) (8). 66

In 2020, the early phase of the COVID-19 pandemic resulted in health system adjustments with 67 68 the need for reallocation of the already limited resources away from the national malaria control of resources to support surveillance and other healthcare services. Concerns about the association 69 of COVID-19 with hospitals or hospital visits and the closure of some health facilities to provide 70 71 services to COVID-19 patients, have changed people's health-seeking behaviour and are among the barriers to access services including, IPTp-SP (9). These events led to disruptions in hospital 72 care and significantly affected access to IPTp-uptake for pregnant women in Sierra Leone. Several 73 74 previous studies on IPTp uptake have focused on the prevalence and predictors of IPTp uptake 75 among pregnant women (10).

Existing research evaluating the uptake of IPTp in Africa and Sierra Leone was more focused on the factors affecting IPTp-uptake with scarce research information on IPTp disaggregated data by region and district and this was not assessed in the recent multi-cluster indicator survey in Sierra Leone (11). Our study aims to assess the impact of COVID-19 on the uptake of Intermittent Preventive Therapy (IPTp) for malaria in pregnancy in Sierra Leone at the district, regional, and national levels to inform national policy around the resiliency of the malaria control programming.

82 Methods

#### 83 Study Design

We conducted a retrospective cross-sectional study using monthly aggregated secondary data on IPTp uptake among pregnant women who access ANC services in their 2<sup>nd</sup> and 3<sup>rd</sup> trimester of pregnancy extracted from the District Health Information system-2 (DHIS2) platform for all the 5 regions of Sierra Leone.

88

#### 89 Study Setting

90 The health system is divided into three tiers: primary health care and extended community health programs, secondary health care, and tertiary health care. The primary healthcare system has 91 92 1430 peripheral health units (PHUs). IPTp is given to pregnant women during routine ANC in PHUs 93 and by community health workers. The current national IPTp policy for IPTp recommends giving SP at 13 weeks of pregnancy with subsequent doses every 4 weeks. We used data on IPTp uptake 94 among pregnant women from all 5 regions in Sierra Leone: Eastern (Kailahun, Kenema, and Kono 95 96 districts), Western Area (Urban and Rural), Northern (Bombali, Falaba, Koinadugu, and Tonkolili 97 districts), Northwest (Kambia, Karene, and Port Loko districts), and the Southern region (Bo, Bonthe, Moyamba, and Pujehun districts). 98

#### 99 Data Sources and Variables

100 Aggregated monthly data on IPTp uptake was extracted from the DHIS-2 platform, a national 101 health information system on September 4, 2023. The data were initially collected from individual patients in the PHUs, aggregated monthly, and then forwarded to the District Monitoring and 102 Evaluation Officers for review and entry into the DHIS-2 platform. Each dose is for one eligible 103 person each month. IPTp1 is the first dose of IPTp given in the 2<sup>nd</sup> or 3<sup>rd</sup> trimester, IPTp2 is the 104 second dose of IPTp given 4 weeks after the first dose, IPTp3+ is the third dose of IPTp given 4 105 106 weeks after the second dose, and any subsequent doses given up until delivery (including the 4<sup>th</sup> to 7<sup>th</sup> doses). 107

Monthly data from January 2019-December 2023 was extracted to capture seasonal variation in
service utilization and to reflect IPTp uptake in three time periods: January 2019-Feb 2020 (before
COVID-19; March 2020-Feb 2022 (during COVID-19); March 2022- December 2022 (after COVID-

- 111 19). Variables extracted included: the number of pregnant women who received IPTp (IPTp1,
- 112 IPTp2, IPTp3+) per month in the second (gestational weeks 13 to 24) and third (gestational weeks
- 113 24 to delivery) trimesters for 16 districts (divided into five regions).

#### 114 Data Management and Analysis

115 The data in Excel format were cleaned, coded, and validated. Analyses and data visualization were

116 performed in STATA (version 15.1 Stata Corp LLC, College Station, TX). We describe and visualize

117 trends over time to demonstrate national and regional variation in IPTp1, IPTp2, and IPTp3+

- 118 uptake before, during, and after COVID-19. The median and interquartile range for each outcome
- in each period was calculated for descriptive statistics.

#### 120 Ethical consideration

121 Ethics approval was obtained from the Sierra Leone Ethics and Scientific Review Committee

122 (SLESRC number: 019/05/2023). Since routinely aggregated data, informed consent did not apply

123 with approval for data extraction and use by the Chief Medical Officer, Ministry of Health, Sierra

124 Leone. Finally, the authors did not have access to information that could identify individual

125 participants during or after data collection.

126 Results

127 Uptake of IPTp before, during and after COVID-19

Data from 14 months of national IPTp uptake before COVID-19, 24 months during COVID-19, and 10 months after COVID-19 were extracted from the DHIS-2. The median monthly uptake of total IPTp was the lowest before COVID-19 (53,244) but increased during COVID-19 (55,257). The exception was the median monthly uptake of IPTp1, which was lowest during COVID-19 (20,338), but highest after COVID-19 (20,914) (*Table 1*).

#### 134 Table 1. Summary of IPT uptake over three time periods in Sierra Leone

	Pre-COVID		During COVID		Post-COVID	
	Mar 2019	9 to Feb 2020	Mar 202	0 to Feb 2022	Mar 2022	2 to Dec 2022
	12 months		24 months		10 months	
	Median	(IQR)	Median	(IQR)	Median	(IQR)
Uptake per month, National						
level						
Total (IPTp-1, IPTp-2, IPTp-	53,244	(52,344;	55,257	(52,908;	59 <i>,</i> 439	(58,670;
3+)		53,662)		57,236)		61,288)
IPTp-1	20,405	(19,491;	20,338	(19,330;	20,914	(20,362;
		21,280)		20,901)		21,914)
IPTp-2	17,757	(16,943;	17,859	(16,882;	19,758	(18,859;
		18,103)		18,725)		20,556)
IPTp-3+	14,597	(13,884;	16,982	(15,756;	18,638	(18,513;
		15,093)		17,861)		19,186)

IPTp (intermittent preventive therapy in pregnancy), IPTp-3+ refers to the 3<sup>rd</sup> dose and beyond). IQR (inter-quartile
 range).

137

138

# 139 Differential uptake of IPTp1, IPTp2, and IPTp3+ before, during and after COVID-19

140 During these three time periods, there were small fluctuations in the uptake of all forms of IPTp

141 (total IPTp, IPTp1, IPTp2 and IPTp3+). Before COVID-19, the IPTp was stable with a decline in all

142 forms of IPTp uptake in the last three months and the start of the COVID-19 period, specifically

143 from January-March 2020. The uptake of all forms of IPTp recovered in the first three months of

the COVID-19 period (until June 2020), with a lower magnitude decline and recovery over a couple

of months before steadily increasing during late COVID-19 and after COVID-19 (Figure 1).

146 IPTp1 uptake is highest in all the periods, with lower IPTp2 and then IPTp3+ uptake across all

147 periods. IPTp2 and IPTp3 both had a more marked increase in uptake following recovery than

148 IPTp1, though all experienced sustained increase after COVID-19 (Figure 1).

149 Geographic variation in the uptake of IPTp before, during and after COVID-19 across the five

150 regions of Sierra Leone

We disaggregated the data by the five regions (East, North, North-West, South, and Western Area) of Sierra Leone to look for regional variation in trends. All regions had stable fluctuations through all time periods and all regions had a similar decline in uptake starting in January 2020, the last three months of the pre-COVID-19 period. Some regions had a sharp increase in total uptake in early 2021, notably the Northern and Eastern regions and the Eastern region had a slower recovery after the decline compared to the other regions (**Figure 2**).

157 Discussion

Using longitudinal aggregate program data, we found a dynamic pattern in the uptake of IPTp over three time periods shaped by the COVID-19 pandemic in Sierra Leone. We observed small fluctuations in the IPTp-SP uptake throughout the three time periods of COVID-19; a decline in uptake of IPTp in the latter part of the pre-COVID-19 period with further decline during the early phase of the COVID-19 pandemic; and a delay in recovery of IPTp uptake in the Eastern region compared to the other four regions of Sierra Leone.

The fluctuations in IPTp throughout all the three time periods could be related to a number of 164 factors that include management of the supply of SP (12), issues of stock-out (13) throughout the 165 three time periods in this study, and seasonal variations of the COVID-19 cases. Despite the 166 challenges in the availability of resources, and the occasional issues of stock-out, the program was 167 168 able to provide a continuous supply of SP for all three IPTp types until the post-COVID-19 period. 169 This was possibly because of the increased programmatic awareness of the challenges affecting the prevention of malaria in pregnancy and especially with the uptake of IPTp uptake (14). A 170 171 qualitative study in Uganda on the barriers to uptake of IPTp revealed that supply side chain

management and refusal of SP account for most of the missed IPTp doses in antenatal care andsuggests the need for IPTp safety reassurance among pregnant women(15).

**Overall**, the most notable finding was a very clear decline in uptake of IPTp that started in January 174 175 2020 that had its nadir prior to the national lockdowns in April 2020, followed by recovery by mid-176 2020, and a further increase by early 2021 and into the post-COVID-19 period. This finding was in the background of an otherwise relatively steady increase over time of uptake of IPTp across all 177 periods and was similar across all geographical regions, except the Eastern region which had a 178 179 slower recovery. The decline in services could have started several months before the country's 180 first case (31 March 2020) and prior to the implementation of lockdown and intercountry travel restriction in April 2020. Preparation for the pandemic began in late 2019 to pre-emptively address 181 population anxiety and community fear rooted in the impact of the 2014-2016 Ebola outbreak in 182 Sierra Leone(16)(17). Government mitigations in that period included shifting resources away 183 184 from all ministries, departments, and agencies to address the needs of the COVID-19 preparedness plan with reports suggesting possible effects on community health worker motivation, low levels 185 of essential drugs in particular at the PHU levels, and limited supply drugs for use at the facilities 186 and communities (18). A systematic review in sub-Saharan Africa confirmed that some of the 187 barriers to improving IPTp uptake are poor leadership and governance, low budgetary allocation, 188 189 low staff motivation, long distances and long waiting times, drug stock outs, and poor 190 management of information and supply chain. Therefore, the need for malaria control programs in Africa to address the barriers to low coverage and program ineffectiveness and prioritize 191 192 increase in the uptake of IPTp to prevent malaria in pregnancy (19).

Across all periods, IPTp1 uptake was highest with lower uptake of IPTp2 and then IPTp3+ across 193 194 all periods with the same pattern observed amongst IPTp1, 2, and 3+ regarding the timing and magnitude of decline and recovery during COVID-19. The recovery and increase IPTp uptake 195 during COVID-19 and post COVID-19 appeared to be more marked with IPTp2 and 3+ such that 196 197 levels converged in the post-COVID-19 period. The recovery phase of IPTp uptake showed a steady increase, which was maintained post-COVID-19. This overall trend of improvement in IPTp 198 199 indicators, particularly of IPTp2 and IPTp3+ across the time periods, reflects some programmatic 200 resiliencies that had just started before COVID-19.

201 Of note, in October 2019, Impact Malaria, a USAID initiative(20) was launched to support the treatment and prevention of malaria in pregnancy. Commencement of training for healthcare 202 workers (including community health workers) on malaria in pregnancy (IPTp uptake and other 203 204 related malaria services) started in October 2020. The slower recovery in the Eastern region could 205 partly be explained by the delay in rolling-out of the malaria in pregnancy initiative in this region, which started in the North and Southern regions before expanding to the Eastern region. Ongoing 206 support to the Community Health Worker initiative continued throughout the study period by the 207 Global Alliance Vaccine Initiative in Kono, Karene, and Bonthe and the U.S. President's Malaria 208 209 Initiative (Sierra Leone) in Kailahun, Falaba, and Pujehun (21).

Our study suggests the need to provide appropriate measures to address supply chain issues, and safety reassurance on the use of IPTp for the prevention of malaria among pregnant women. There is also the need to have a system in place at national, regional, and district levels that addresses emergency preparedness and readiness in disease outbreaks using a risk management approach to ensure that essential services continue uninterrupted.

215	The strength of the study is that the use of data from district-level programme information
216	collected as part of routine monitoring and evaluation from a national public system should be
217	representative of the country. Study limitations are the magnitude of data computation required,
218	and the reliance on the human element for data transfer, input, and data abstraction that could
219	impact the data in the DHIS-2 platform that was used for this analysis.
220	Conclusion
221	There has been progress with IPTp uptake that created some resiliency in services during the
222	COVID-19 pandemic so that incremental progress could continue. Nonetheless, a critical piece of
223	pandemic preparedness and early response should incorporate planning so that ongoing services,
224	including those at the community level, are continued without interruption. Ongoing technical
225	resource assistance through programs like Impact Malaria was an effective strategy in the medium
226	term for creating resiliency in services addressing malaria in pregnancy.

## 228 Declaration section

229 The authors declared no conflict of interest

#### 230 Acknowledgements

- 231 We acknowledge the staff and members of National Malaria Control Program of the Ministry of
- Health for providing the enabling environment to conduct this study. We thank Kristy Yiu (Unity
- Health Toronto) for her early support in coordination of the project. Finally, we thank the staff of
- 234 Sustainable Health System for their support. SM is supported by a Tier 2 Canada Research Chair in
- 235 Mathematical Modeling and Program Science.
- **Funding:** This study was conducted with support from the Canadian Institute of Health Research:
- **237** (grant number: CIHR: WI1-179883).
- 238 Conflict of interest: None to declare
- 239 Author's contribution:
- 240 Conceptualization and study design: WTP, ML, SL, SS
- 241 Data curation and validation: WTP, MSK , BS, WKL, AMF
- 242 Methodology and formal analysis: BM, WTP, ML, MSK, SM
- 243 Funding acquisition, resources, supervision: SS, SL, SM, ACK
- 244 Writing original draft preparation: WTP, ML, ACK
- 245 Writing review & editing: MSK, BS, WKL, AMF, SM, SS, SL
- 246 Availability of data: The dataset (<u>https://doi.org/10.5061/dryad.4tmpg4fmx</u>) is available from:
- 247 https://datadryad.org/stash/dashboard.
- 248
- 249

# 250 References

251	1. Ngaba NN, Askemdet O, Junsay JPN, Yanamala M, Patel S, Hange N, et al. The Impact o
252	Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine on Pregnant Women and
253	Newborns at Bon Samaritain. Advances in Sexual & Reproductive Health Research [Internet]
254	2024 Jan 4 [cited 2024 Sep 29];3(1):1–12. Available from
255	https://www.opastpublishers.com/peer-review/the-impact-of-intermittent-preventive-
256	treatment-with-sulphadox in e-pyrime tham in e-on-pregnant-women-and-new borns-at-bon-sa-sa-sa-sa-sa-sa-sa-sa-sa-sa-sa-sa-sa-
257	6749.html
258	2. Guyatt HL, Snow RW. Impact of Malaria during Pregnancy on Low Birth Weight in Sub-Saharar
259	Africa. Clin Microbiol Rev [Internet]. 2004 Oct [cited 2024 Oct 2];17(4):760–9. Available from
260	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC523568/
261	3. Morgan HG. Placental malaria and low birthweight neonates in urban Sierra Leone. Ann Trop
262	Med Parasitol. 1994 Dec;88(6):575–80.
263	4. Rogerson SJ, Mwapasa V, Meshnick SR. Malaria in Pregnancy: Linking Immunity and
264	Pathogenesis to Prevention [Internet]. Defining and Defeating the Intolerable Burden of Malaria
265	III: Progress and Perspectives: Supplement to Volume 77(6) of American Journal of Tropica
266	Medicine and Hygiene. American Society of Tropical Medicine and Hygiene; 2007 [cited 2023
267	Mar 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1710/
268	5. Prevalence and predictors of anemia among pregnant women in Ethiopia: Systematic review
269	and meta-analysis   PLOS ONE . [cited 2024 Sep 30]. Available from
270	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267005

271	6. Yaya S, Uthman OA, Amouzou A, Bishwajit G. Use of Intermittent Preventive Treatment amor
272	Pregnant Women in Sub-Saharan Africa: Evidence from Malaria Indicator Surveys. Trop Me
273	Infect Dis [Internet]. 2018 Feb 11 [cited 2023 Mar 29];3(1):18. Available fror
274	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136633/
275	7. Kamau A, Musau M, Mwakio S, Amadi D, Nyaguara A, Bejon P, et al. Impact of Intermitte
276	Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenya
277	Coast. Clin Infect Dis [Internet]. 2022 Jun 22 [cited 2024 Oct 1];76(3):e875–83. Available fror
278	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907553/
279	8. Anto F, Agongo IH, Asoala V, Awini E, Oduro AR. Intermittent Preventive Treatment of Malar
280	in Pregnancy: Assessment of the Sulfadoxine-Pyrimethamine Three-Dose Policy on Bir
281	Outcomes in Rural Northern Ghana. Journal of Tropical Medicine [Internet]. 2019 [cited 202
282	Oct 1];2019(1):6712685. Available from
283	https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685
283 284	https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685 9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Afric
283 284 285	<ul> <li>https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685</li> <li>9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Afric A Preliminary Analysis. Trop Med Infect Dis [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):6</li> </ul>
283 284 285 286	<ul> <li>https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685</li> <li>9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Afric A Preliminary Analysis. Trop Med Infect Dis [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):6 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863638/</li> </ul>
283 284 285 286 287	<ul> <li>https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685</li> <li>9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Afric A Preliminary Analysis. Trop Med Infect Dis [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):6 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863638/</li> <li>10. Buh A, Kota K, Bishwajit G, Yaya S. Prevalence and Associated Factors of Taking Intermittee</li> </ul>
283 284 285 286 287 288	<ul> <li>https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685</li> <li>9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Afric A Preliminary Analysis. Trop Med Infect Dis [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):6 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863638/</li> <li>10. Buh A, Kota K, Bishwajit G, Yaya S. Prevalence and Associated Factors of Taking Intermittee Preventive Treatment in Pregnancy in Sierra Leone. Trop Med Infect Dis [Internet]. 2019 Feb</li> </ul>
283 284 285 286 287 288 289	<ul> <li>https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685</li> <li>9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Afric A Preliminary Analysis. Trop Med Infect Dis [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):6 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863638/</li> <li>10. Buh A, Kota K, Bishwajit G, Yaya S. Prevalence and Associated Factors of Taking Intermittee Preventive Treatment in Pregnancy in Sierra Leone. Trop Med Infect Dis [Internet]. 2019 Feb [cited 2023 Mar 29];4(1):32. Available from</li> </ul>
283 284 285 286 287 288 288 289 290	<ul> <li>https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685</li> <li>9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Africe A Preliminary Analysis. Trop Med Infect Dis [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):6 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863638/</li> <li>10. Buh A, Kota K, Bishwajit G, Yaya S. Prevalence and Associated Factors of Taking Intermittee Preventive Treatment in Pregnancy in Sierra Leone. Trop Med Infect Dis [Internet]. 2019 Feb [cited 2023 Mar 29];4(1):32. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473366/</li> </ul>
283 284 285 286 287 288 289 290 291	<ul> <li>https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685</li> <li>9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Afric A Preliminary Analysis. Trop Med Infect Dis [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):6 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863638/</li> <li>10. Buh A, Kota K, Bishwajit G, Yaya S. Prevalence and Associated Factors of Taking Intermitted Preventive Treatment in Pregnancy in Sierra Leone. Trop Med Infect Dis [Internet]. 2019 Feb [cited 2023 Mar 29];4(1):32. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473366/</li> <li>11. Sierra Leone - Multiple Indicator Cluster Survey 2000 [Internet]. [cited 2024 Oct 1]</li> </ul>

293	12. Ndu A, Mbachu C, Anitube O, Ezeoke U. Inequities in the use of sulphadoxine-					
294	pyrimethamine for malaria prophylaxis during pregnancy in Nigeria. Malawi Med J [Internet].					
295	2020 Mar [cited 2024 Oct 2];32(1):45–51. Available from:					
296	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366158/					
297	13. Lahuerta M, Sutton R, Mansaray A, Eleeza O, Gleason B, Akinjeji A, et al. Evaluation of					
298	health system readiness and coverage of intermittent preventive treatment of malaria in infants					
299	(IPTi) in Kambia district to inform national scale-up in Sierra Leone. Malar J [Internet]. 2021 Feb					
300	6 [cited 2024 Oct 2];20:74. Available from:					
301	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866768/					
302	14. WHO-HTM-GMP-2014.4-eng.pdf. [cited 2024 Oct 2]. Available from:					
303	https://iris.who.int/bitstream/handle/10665/338350/WHO-HTM-GMP-2014.4-					
304	eng.pdf?sequence=2					
305	15. Rassi C, Graham K, King R, Ssekitooleko J, Mufubenga P, Gudoi SS. Assessing demand-side					
306	barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative					
307	study in two regions of Uganda. Malaria Journal [Internet]. 2016 Nov 4 [cited 2024 Oct					
308	2];15(1):530. Available from: https://doi.org/10.1186/s12936-016-1589-7					
309	16. Murray RT, Drew LB, Memmott C, Bangura YM, Maring EF. A community's experience					
310	) during and after the Ebola epidemic of 2014—2016 in Sierra Leone: A qualitative study. PLoS					
311	Negl Trop Dis [Internet]. 2021 Feb 25 [cited 2024 Oct 2];15(2): e0009203. Available from:					
312	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954283/					
313	17. O'Leary A, Jalloh MF, Neria Y. Fear and culture: contextualising mental health impact of the					
314	2014–2016 Ebola epidemic in West Africa. BMJ Glob Health [Internet]. 2018 Jun 22 [cited 2024					

315	Oct	2];3(3):	e000924.	Available	from:
316	https:/,	/www.ncbi.nlm.nih.gov/p	mc/articles/PMC6035506	/	
317	18. Bh	aumik S, Moola S, Tyagi J,	Nambiar D, Kakoti M. Con	nmunity health workers	for pandemic
318	respon	se: a rapid evidence synth	nesis. BMJ Glob Health [In	ternet]. 2020 Jun 10 [ci	ted 2024 Oct
319	2];5(6):	e002769. Available from	: https://www.ncbi.nlm.n	ih.gov/pmc/articles/PM	C7292038/
320	19. Th	iam S, Kimotho V, Gatong	ga P. Why are IPTp covera	age targets so elusive in	sub-Saharan
321	Africa?	A systematic review of he	ealth system barriers. Mala	ar J [Internet]. 2013 Oct	3 [cited 2024
322	Oct 2];	12:353. Available from: h	ttps://www.ncbi.nlm.nih.	gov/pmc/articles/PMC3	850646/
323	20. PN	/I_Impact_Malaria_Annu	al_Report_Year3.pdf [Inte	ernet]. [cited 2024 Oct	2]. Available
324	from:				
325	https:/,	/assets.speakcdn.com/ass	sets/2594/PMI_Impact_N	alaria_Annual_Report_`	Year3.pdf
326	21. U.	S. President's Malaria Initi	ative: Sierra Leone Malari	a Operational Plan FY 20	)23. Available
327	at: htt	ps://www.pmi.gov/resour	rces/malaria-operational-	plans-mops/. Accessed	January 14,
328	2025.				
329					



Figure 1: Total IPTp and IPTp 1,2 and 3+ receipt per month in Sierra Leone, over three time periods. IPTp (Intermittent Preventive Therapy).

# Figure



Figure 2: Total IPTp (intermittent preventive therapy) during pregnancy, received per month over three time periods in the five regions in Sierra Leone.

